COMPARISON OF IN-HOSPITAL OUTCOME IN MEN VERSUS WOMEN TREATED BY EITHER THROMBOLYTIC THERAPY OR PRIMARY CORONARY ANGIOPLASTY FOR ACUTE MYOCARDIAL-INFARCTION

At 12 centers, 395 patients, including 288 men (73%) and 107 women (27%) with acute myocardial infarction (AMI), were prospectively randomized to treatment with tissue plasminogen activator (t-PA) or primary percutaneous transluminal coronary angioplasty (PTCA). Compared with men, women were older (65.7 vs 57.7 years, p <0.0001), more often had diabetes mellitus (19% vs 10%, p = 0.03), systemic hypertension (54% vs 39%, p = 0.005), prior congestive heart failure (5% vs 0%, p = 0.002), and presented later after symptom onset (229 vs 174 minutes, p = 0.0004). The in-hospital mortality in women was 3.3-fold higher than men (9.3% vs 2.8%, p = 0.005); After adjustment for comorbid baseline characteristics, however, only advanced age independently correlated with mortality. Among t-PA-treated patients, mortality was significantly higher-in women than in men (14.0% vs 3.5%, p = 0.006). intracranial hemorrhage after t-PA was also more common in women than in men (5.3% vs 0.7%, p = 0.037). In contrast, women and men had similar in-hospital mortality after primary PTCA (4.0% vs 2.1%, respectively p = 0.46). No intracranial bleeding occurred in PTCA-treated patients. A univariate trend was present for reduced in-hospital mortality in women treated with PTCA rather than t-PA (4.0% vs 14.0%, p = 0.07). By multiple logistic regression analysis of 15 clinical variables, treatment with PTCA rather than t-PA, as well as younger age, were independently predictive of in-hospital survival in women. In men, in-hospital mortality was similar with both t-PA and PTCA (3.5% vs 2.1%, respectively, p = 0.46); only advanced age independently correlated with mortality in men. Compared with men, women with AMI are at increased risk for early mortality and life-threatening hemorrhagic complications after thrombolytic therapy Primary PTCA reduces the risk of intracranial bleeding and results in improved survival in women, such that the prognosis of men and women is equally favorable.